• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>RailAmerica

RailAmerica

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Research and Markets: PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023

    Research and Markets: PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023

  2. Research and Markets: PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023: France, Germany, Italy, Spain, UK

    Research and Markets: PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023: France, Germany, Italy, Spain, UK

  3. Research and Markets: PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis to 2023

    Research and Markets: PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis to 2023

  4. Research and Markets: Astellas's (Also known as ASP015K) Peficitinib Rheumatoid Arthritis Drug Forecast and Market Analysis to 2023

    Research and Markets: Astellas's (Also known as ASP015K) Peficitinib Rheumatoid Arthritis Drug Forecast and Market Analysis to 2023

  5. Research and Markets: Vertex's Decernotinib (Phase III-ready JAK3 inhibitor) Rheumatoid Arthritis Forecast and Market Analysis to 2023

    Research and Markets: Vertex's Decernotinib (Phase III-ready JAK3 inhibitor) Rheumatoid Arthritis Forecast and Market Analysis to 2023

  6. Research and Markets: UCB's Cimzia (certolizumab pegol) Rheumatoid Arthritis Drug Forecast and Market Analysis to 2023

    Research and Markets: UCB's Cimzia (certolizumab pegol) Rheumatoid Arthritis Drug Forecast and Market Analysis to 2023

  7. Research and Markets: PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023

    Research and Markets: PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis to 2023

  8. Research and Markets: PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis to 2023

    Research and Markets: PharmaPoint: Rheumatoid Arthritis - China Drug Forecast and Market Analysis to 2023

  9. Research and Markets: Alder Biopharmaceuticals's Clazakizumab (Rheumatoid Arthritis) Analysis - Forecast and Market Analysis to 2023

    Research and Markets: Alder Biopharmaceuticals's Clazakizumab (Rheumatoid Arthritis) Analysis - Forecast and Market Analysis to 2023

  10. Cipher Pharmaceuticals acquires Canadian rights to novel treatment for psoriasis and rheumatoid arthritis

    Cipher Pharmaceuticals acquires Canadian rights to novel treatment for psoriasis and rheumatoid arthritis

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.